MBX Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
MBX$54.06+5.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $161,691 | $75,289 |
| Marketable securities | 319,903 | 298,416 |
| Prepaid expenses and other current assets | 11,168 | 7,834 |
| Total current assets | 492,762 | 381,539 |
| Property and equipment, net | 4,999 | 2,735 |
| Right-of-use assets | 2,610 | 487 |
| Other assets | 247 | 383 |
| Total assets | $500,618 | $385,144 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $6,805 | $2,977 |
| Accrued expenses | 17,575 | 12,346 |
| Operating lease liabilities, current | 787 | 172 |
| Total current liabilities | 25,167 | 15,495 |
| Share repurchase liability | — | 2 |
| Operating lease liabilities, net of current | 2,504 | 424 |
| Total liabilities | 27,671 | 15,921 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized and zero issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 500,000,000 shares authorized and 49,640,833 issued and outstanding as of September 30, 2026 and 500,000,000 shares authorized and 44,927,953 issued and outstanding as of December 31, 2025 | 6 | 6 |
| Additional paid-in-capital | 822,408 | 593,407 |
| Accumulated deficit | (347,509) | (224,476) |
| Accumulated other comprehensive (loss) income | (1,958) | 286 |
| Total stockholders’ equity | 472,947 | 369,223 |
| Total liabilities and stockholders’ equity | $500,618 | $385,144 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.